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Abstract
Background: The present study explores the efficacy and toxicity of combining a new, non-toxic,
cancer treatment modality, termed Tumor Treating Fields (TTFields), with chemotherapeutic
treatment in-vitro, in-vivo and in a pilot clinical trial.
Methods: Cell proliferation in culture was studied in human breast carcinoma (MDA-MB-231) and
human glioma (U-118) cell lines, exposed to TTFields, paclitaxel, doxorubicin, cyclophosphamide
and dacarbazine (DTIC) separately and in combinations. In addition, we studied the effects of
combining chemotherapy with TTFields in an animal tumor model and in a pilot clinical trial in
recurrent and newly diagnosed GBM patients.
Results: The efficacy of TTFields-chemotherapy combination in-vitro was found to be additive
with a tendency towards synergism for all drugs and cell lines tested (combination index ≤ 1). The
sensitivity to chemotherapeutic treatment was increased by 1–3 orders of magnitude by adjuvant
TTFields therapy (dose reduction indexes 23 – 1316). Similar findings were seen in an animal tumor
model. Finally, 20 GBM patients were treated with TTFields for a median duration of 1 year. No
TTFields related systemic toxicity was observed in any of these patients, nor was an increase in
Temozolomide toxicity seen in patients receiving combined treatment. In newly diagnosed GBM
patients, combining TTFields with Temozolomide treatment led to a progression free survival of
155 weeks and overall survival of 39+ months.
Conclusion:  These results indicate that combining chemotherapeutic cancer treatment with
TTFields may increase chemotherapeutic efficacy and sensitivity without increasing treatment
related toxicity.
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Background
A new physical cancer treatment modality termed Tumor
Treating Fields, or TTFields, has recently been demon-
strated to be highly effective when applied to cell cultures,
animal cancer models, as well as to patients suffering from
locally advanced and or metastatic solid tumors [1-3]. In
a pilot clinical trial, the medians of time to disease pro-
gression and overall survival of recurrent GBM patients
treated by TTFields alone were more than double the
reported medians of historical control patients [1]. In con-
trast to the widely used physical treatment modality, ion-
izing radiation, TTFields are not associated with
significant side effects.
TTFields are low intensity (1–2 V/cm), intermediate fre-
quency (100 – 200 kHz) alternating electric fields gener-
ated by special insulated electrodes applied to the skin
surface. These specially tuned fields have no effect on qui-
escent cells while having an anti-mitotic effect on dividing
cells. During cytokinesis, TTFields generate non-uniform
intracellular fields that exert forces that move polar mac-
romolecules and organelles towards the narrow neck, sep-
arating the newly forming daughter cells, by a process
termed dielectrophoresis. These molecular and organelle
movements, together with an interference with the spin-
dle tubulin polymerization process, inhibit cell division
and lead to cell death[2]. Fortunately, the dividing cells of
the hematopoietic system are not affected by TTFields as
the muscles surrounding the marrow containing bones
serve as an effective electric field shield. Moreover, due to
their relatively high frequency range and very low inten-
sity, TTFields do not stimulate nerves and muscles, do not
generate meaningful temperature elevation or puncture
the cell membrane (as the strong electroporation fields do
[4]). Thus, TTFields are not associated with meaningful
toxicity in contrast to most anti-cancer agents currently in
use [5].
In view of the unfavorable therapeutic indexes of the
available effective chemical and physical (i.e. ionizing
radiation) therapeutic agents, many cancer treatment pro-
tocols require simultaneous or sequential use of a number
of therapeutic agents in an attempt to increase efficacy
while maintaining tolerable toxicity [5-7]. Within this
framework it is generally accepted that by adding ionizing
radiation [8] to chemotherapy one gets both the benefit of
the radiation effect as well as sensitization leading to an
increased efficacy without a corresponding increase in tox-
icity. On the basis of the above this study explores the
potential use of the new physical treatment modality,
TTFields, in combination with chemotherapeutic agents
in cell cultures, an animal tumor model, as well as in
patients with glioblastoma (GBM). As TTFields are not
associated with systemic toxicity [1] the expectation is that
their addition will result in an increase in efficacy alone.
Methods
Cell cultures
Cells were cultured and maintained as previously
described [1,2]. In brief: Human breast cancer (MDA-MB-
231) and human glioma (U-118) obtained from ATCC
(USA) were cultured in DMEM + 10% FCS media in a 5%
CO2 incubator at 37°C. Drops consisting of 200 μl sus-
pension of cells (100 × 103 cells/ml) were placed at the
centre of 35 mm Petri dishes, incubated for 2 hours to
allow for cell attachment, then 1.5 ml of media were
added and incubation was continued for an additional 22
h. Following this, the baseline cell count was estimated
using the XTT colorimetric method (expressed as OD0).
The media in the Petri dishes was replaced by fresh media
(3 ml), with or without a chemotherapeutic agent and
incubated at a final temperature of 37° ± 0.5°C for 24 to
72 hours after which the cell number was re-estimated
(OD1). The relative number of viable cells at each time
point following baseline was expressed as OD1/OD0 and
treatment efficacy as the % change in proliferation relative
to control:
(OD1/OD0)experiment * 100/(OD1/OD0)control (1)
TTFields treatment of cultures
As previously described [1,2], two pairs of electrodes,
insulated by a high dielectric constant ceramic, were posi-
tioned normal to each other at a distance of 20 mm in
treatment and control dishes. In the former, the electrodes
were connected to sinusoidal waveform generator that
generated fields of optimal frequencies in the medium
[1,2,9]: 150 kHz for breast cancer and 200 kHz for glioma,
that changed direction by 90° every 250 ms. Field inten-
sity was measured as described previously [2] and
expressed as V/cm. For 72 h experiments the TTFields
intensity of 1.75 V/cm was used. For 24 h experiments
0.65, 1.25 and 1.75 V/cm TTFields were used.
Four different sets of experiments were conducted in con-
junction with each chemotherapeutic agent: untreated
sham control, treatment with TTFields, treatment with the
chemotherapeutic agents, and combined TTFields –
Chemo treatment.
Assessment of combination Index and dose reduction 
index
The Chou and Talalay [10] method for assessing the com-
bined effect of multiple drugs was used for the drug –
TTFields combinations. In order to assess whether the
interactions between TTFields and each of the chemother-
apeutic agents is synergistic, additive or antagonistic, com-
bination indexes were calculated as follows; TTFields
intensity replaced the concentration (dose) variable in the
analyses. Dose-response curves were generated for
TTFields and each drug to determine the median effectBMC Medical Physics 2009, 9:1 http://www.biomedcentral.com/1756-6649/9/1
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points. Variable ratios of drug concentrations to TTFields
intensities were used to calculate the Combination
Indexes (CI) as follows:
CI = (CDrug(incombination), X% effect/CDrug(alone), X% effect) + (ITT-
Fields(incombination), x% effect /ITTFields(alone), X% effect)( 2 )
Where: C are the drug concentrations and I the TTFields
intensities use to achieve a preset X% effect. Relationships
of CI<1 indicate more than additive – synergy, CI = 1
reflects additivity – summation and CI>1 indicates less
than additive or antagonism.
In order to asses whether TTFields increase the sensitivity
of tumor cells to various chemotherapeutic agents, the
dose reduction index (DRI) of for each of these agents was
calculated according to [11]. In short, the median-effect
plots were for each chemotherapy-TTFields combination,
were constructed. The ratio of affected to unaffected
number of cells (fa/fu) was plotted versus drug concentra-
tion on a log-log scale. The median effect point (Dm) was
assessed by deriving the slope of the linear regression for
each of the plots. The DRI for a 50% effect (DRIm) was cal-
culated as the ratio of Dm for drug alone and for combined
drug-TTFields:
DRIm = Dm(drugalone)/Dm(combinedtreatment) (3)
A DRI greater than 1 indicates an increase in sensitivity to
the drug. The greater the DRI, the more significant the
possible dose reduction.
In-vivo experiments
Combined TTFields and Paclitaxel efficacy study in VX2
tumor bearing rabbits was conducted after approval by
the NovoCure Internal Animal Care and Use Committee.
All painful or anxiogenic procedures were performed
under general anesthesia induced by intramuscular
administration of 30 mg/kg of ketamine hydrochloride,
10 mg/kg xylazine hydrochloride and 1.5 mg/kg Acepro-
mazine. The tumor tissue required for implantation was
obtained from VX-2 tumor bearing carrier rabbits. The car-
rier rabbits had VX-2 tumors implanted intramuscularly
in the thigh. When the tumor reached approximately 1 cm
in diameter (about 3 weeks from implantation), the
tumor was excised, minced in sterile saline and VX-2
tumor fragments obtained. Two fragments were injected
using a large bore needle into the thigh muscles of both
legs in a recipient rabbit for tumor propagation. For exper-
imental animals, after laparotomy, a fragment of tumor
tissue (1 mm3) was implanted beneath the kidney capsule
of the recipient rabbit.
The current experiment comprised 28 animals (7 in each
of 4 groups). Fourteen days after tumor implantation the
initial tumor volume was assessed based on serial (2.2
mm interval) T1 weighted axial MRI images (1.5 Tesla, GE
Genesis-Signa) obtained 3 minutes following IV injection
of 3 ml of Gadolinium. Tumor volume was assessed from
the area of the contrast enhancing lesion in each section.
The animals were assigned randomly into 4 groups before
treatment start:
1. TTFields treated group: TTFields were applied by using
the NovoTTF-100A device (NovoCure LTD., Haifa, Israel).
An optimal frequency of 150 kHz and intensity of 1–2 V/
cm were used. TTFields were switched sequentially
between two perpendicular field directions.
2. Control group: sham electrode heated to mimic heat
generated by the TTFields treatment. (38–39.9°C)
3. Paclitaxel (Medixel Injection., Taro Pharmaceutical
Industries LTD., Israel) treated group: 5 mg/animal
diluted in 100 ml of normal saline were infused intrave-
nously over a period of 30 minutes. Premedication was
given subcutaneous 8 hours before and immediately prior
to Paclitaxel administration (Dexamathasone (Dexaveto-
0.2 veterinary, V.M.D n.v/s.a Belgium) 0.5 mg/animal;
Pramine (Metoclopramide HCL, Rafa Laboratories LTD.,
Israel) 1 mg/animal; Diphenhydramine (10%, Medical
M., Israel) 10 mg/animal).
4. Combined TTFields and Paclitaxel treatment as above.
TTFields were delivered to awake and behaving rabbits
through four insulated electrode arrays placed circumfer-
entially around the animal's abdomen, caudal to the rib-
cage. The electrode insulation consisted of a high
dielectric constant (>10,000) ceramic (PMN-PT) allowing
efficient energy transfer through the insulation into the
animals body at the given frequencies. The electrodes
were connected by a spiral cable to a swivel mechanism at
the top of the cage, enabling the free movement. TTFields
were generated using the NovoTTF-100A system (Novo-
Cure Ltd., Haifa, Israel). The animals were treated for 21
days continuously with MRI performed on days 14 and 21
for tumor volume assessment. The TTFields intensity
within the kidneys of the rabbits, using this electrode con-
figuration, is between 1–3 V/cm (based on both finite ele-
ment mesh simulations and direct measurements using
an invasive probe – data not shown).
Pilot clinical trial
A single arm, pilot trial of the safety and efficacy of
TTFields treatment was performed in 20 patients with his-
tologically proven glioblastoma multiforme (GBM) that
met the inclusion/exclusion criteria specified in Supple-
mental Material Appendix A (briefly, KPS 70–100%, Age
≥ 18). The trial was performed according to a protocolBMC Medical Physics 2009, 9:1 http://www.biomedcentral.com/1756-6649/9/1
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approved by the Na Homolce Institutional Review Board
and the Czech Republic Ministry of Health. The patients
were divided into two groups: The first group included 10
patients with recurrent GBM treated with TTFields alone
following failure of maintenance Temozolomide [1]. The
second group consisted of 10 newly diagnosed patients
who were at least 4 weeks post radiation therapy, who
received TTFields combined with maintenance Temozolo-
mide. Prior to initiation of treatment, all patients under-
went a baseline contrast MRI of the head, chest
radiograph, EEG, ECG, complete blood & urine analyses,
physical examination and neurological status. The
patients were hospitalized for 1–3 days for observation
and then released home where they received multiple 4-
week courses of continuous NovoTTF-100A treatment
until progression. The patients were seen once/month at
an outpatient clinic where they underwent an examina-
tion similar to the initial one. TTFields were applied to the
patients using the NovoTTF-100A device set to deliver 200
kHz, 0.7 V/cm (RMS) fields (at the center of the brain) in
2 perpendicular directions, 1 second in each direction
sequentially. The TTFields were applied continuously
using four insulated electrode arrays, each having a sur-
face area of 22.5 cm2, placed on opposing sides of the
head with the tumor positioned directly between the elec-
trode pairs [1]. As previously reported, to avoid electroly-
sis at the electrode surface and intracellular ion
concentration changes that accompany long term current
application, the electrodes were completely insulated by a
ceramic having a very high dielectric constant (>10,000)
that allowed the generation of the necessary electric fields
[1,2]. Using this electrode configuration, the lowest
TTFields intensity at the center of the brain was 0.7 V/cm
(RMS). This intensity was calculated using finite element
mesh simulations and verified by direct measurement in
large animals and a human volunteer [1].
The outcome endpoints of the study included safety, over-
all survival (OS) and progression free survival (PFS).
Assessment of tumor response was based on monthly
MRIs according to the Macdonald criteria [12]. Median
OS and PFS were determined using Kaplan Meier curves
[13]. In the first group, PFS in NovoTTF-100A treated
patients was compared to a matched group of concurrent
control patients who received salvage chemotherapy at
recurrence (n = 18). PFS in Temozolomide/NovoTTF-
100A treated patients was compared to the PFS of a
matched group of concurrent control patients (n = 32)
who received Temozolomide alone (according to the pro-
tocol described by Stupp et al. [14]). OS in both groups
was compared to matched historical control data with the
same Karnofsky performance score (>60) and age [14].
Results
Breast cancer cell cultures
Dose – response of culture exposure to TTFields, paclitaxel, 
doxorubicin and cyclophosphamide, alone and in combination
The relationship between TTFields intensity, at 150 kHz,
and cell proliferation rate is given in Figure 1A. At the low-
est field intensity of 0.63 V/cm there is no significant
change in cell proliferation. For TTFields intensities of
1.25, 1.75 and 2.95 V/cm cell proliferation decreases
(control = 100%) to: 90 ± 3%, 74 ± 4% and 25 ± 5%,
respectively. The dose-response curves of cells exposed to
paclitaxel, doxorubicin and cyclophosphamide, alone
and in combination with 1.75 V/cm TTFields for 72
hours, are given in Figures 1B, C & D. For each drug alone
there is a decrease in cell proliferation with increase in
concentration. For cyclophosphamide and doxorubicin
complete inhibition of proliferation is achieved at high
drug concentrations. For paclitaxel, the inhibitory effect of
the drug saturates at about 300 nM, near the 13% level,
indicating that a fraction of the cells are insensitive to the
agent. Combined treatment with TTFields and each of the
chemotherapeutic agents caused a leftward shift of the
dose response curves. This shift can be expressed as a
decrease in the drug concentration leading to 50% inhibi-
tion of cell proliferation (IC50 – Table 1).
Time course of the effects TTFields, paclitaxel, doxorubicin and 
cyclophosphamide
Figure 2 displays the time course of proliferation inhibi-
tion during a continuous 72 hour exposure to TTFields,
paclitaxel, doxorubicin and cyclophosphamide alone and
in combination with 1.75 V/cm TTFields. It is seen that in
all cases the inhibition during combined exposure is
greater than for the chemotherapeutic agent alone. The
differences between the separate and combined effects
increase with time.
Recovery from treatment
Figure 3 demonstrates that a 24 hour exposure to individ-
ual chemotherapeutic agents induces a reduction of
approximately 25% in viable cell number compared to
Table 1: IC50 for chemotherapeutic drugs alone and in combination with 1.75 V/cm TTFields after 72 hours of continuous treatment.
Chemotherapy IC50 (drug alone) IC50 (drug-TTFields combination)
Paclitaxel 5.00 nM 0.005 nM
Doxorubicin 0.04 μM 0.002 μM
Cyclophosphamide 6.60 mM 0.044 mMBMC Medical Physics 2009, 9:1 http://www.biomedcentral.com/1756-6649/9/1
Page 5 of 13
(page number not for citation purposes)
controls. The proliferation rate (slope of the graph) recov-
ers almost completely during the following 48 hours,
except for doxorubicin, where recovery is slower and
delayed by about 24 hours. In contrast, addition of
TTFields to any one of these chemotherapeutic agents
results in irreversible and complete inhibition of cell pro-
Effect of 72 hour continuous application of TTFields and chemotherapeutic agents, separately and in combination on the cell  proliferation of ER-negative MDA-MB-231 cells (presented as percent viable cells compared to control) Figure 1
Effect of 72 hour continuous application of TTFields and chemotherapeutic agents, separately and in combina-
tion on the cell proliferation of ER-negative MDA-MB-231 cells (presented as percent viable cells compared to 
control). (A) Percent viable cells vs. TTFields intensity. Effect of different concentrations of paclitaxel (B), doxorubicin (C) and 
cyclophosphamide (D), alone and in combination with TTFields of 1.75 V/cm. In B, C and D Filled Circles – represent drug 
alone; Filled Squares – drug in combination with TTFields. Each point represents mean values ± SEM of 18 to 36 replicate 
measurements. Dotted lines demarcate the IC50 values for each curve.
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liferation rate manifested as a decrease in the number of
cells in culture. For Cyclophosphamide there is an almost
complete loss of viable cells after 72 hours of combined
treatment.
Glioma cell cultures
Combined effect of DTIC and TTFields in human glioma cell cultures
In order to asses the combination between Temozolo-
mide and TTFields in glioma cells, DTIC and TTFields
Time course of the effects of 72 hour exposure of MDA cells to Paclitaxel (A), Doxorubicin (B) and Cyclophosphamide (C)  alone and in combination with 1.75 V/cm TTFields Figure 2
Time course of the effects of 72 hour exposure of MDA cells to Paclitaxel (A), Doxorubicin (B) and Cyclophos-
phamide (C) alone and in combination with 1.75 V/cm TTFields. Each graph shows the number of viable cells in cul-
ture over time in control cells (interrupted lines), drug alone (open squares), TTFields alone (open circles) and drug-TTFields 
combination (closed squares). Data are presented as mean ± SEM. Each experimental condition included 18–36 samples.
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were applied alone and in combination to U-118 cells in
culture. Both DTIC and Temozolomide act through a
common degradation product (MTIC). Thus light acti-
vated DTIC was used for these experiments as described
previously [15,16]. Figure 4 compares the DTIC dose-
response curve, with that obtained with DTIC – TTFields
combination. As we have shown in breast cancer cultures,
the addition of TTFields to a chemotherapeutic agent
Time course of recovery from 24 hour exposure to Paclitaxel (A), Doxorubicin (B) and Cyclophosphamide (C) alone and in  combination with 1.75 V/cm TTFields Figure 3
Time course of recovery from 24 hour exposure to Paclitaxel (A), Doxorubicin (B) and Cyclophosphamide (C) 
alone and in combination with 1.75 V/cm TTFields. Each graph shows the number of viable cells in culture over time in 
control cells (interrupted lines), drug alone (open squares), TTFields alone (open circles) and drug-TTFields combination 
(closed squares). Data are presented as mean ± SEM. Each experimental condition included 18–36 samples.
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causes a leftward shift in the dose-response curve in gli-
oma cells as well. The IC50 for DTIC alone in Figure 4 is 6.4
mM, whereas the IC50 for combined DTIC-TTFields is two
orders of magnitude lower (0.023 mM).
Analysis of combination efficacy and sensitivity in-vitro
Combination indexes
The mode of interaction between TTFields and chemo-
therapeutic agents (synergism, additivity or antagonism)
can be analyzed using Combination Indexes (CI) as
described by [10,17]. In order to calculate the CIs for
TTFields-Chemotherapeutic agents, the extent of inhibi-
tion of cell growth was assessed after 24 hours of treat-
ment with Paclitaxel, Doxorubicin and
Cyclophosphamide alone or in combination with differ-
ent intensities of TTFields (0.625–1.75 V/cm; see Materi-
als and Methods). Table 2 demonstrates that for breast
cancer cells the CI for Doxorubicin is very close to 1, indi-
cating additivity [10,11]. In contrast, for TTFields with
Paclitaxel and Cyclophosphamide the CIs are <1 indicat-
ing additivity with a tendency towards synergism.
Dose reduction indexes
In order to assess the extent of possible chemotherapeutic
dose reduction when applied in combination with
TTFields, dose reduction indexes (DRI) for each drug-
TTFields combination were calculated based on the meth-
odology described by [11]. The DRIs for TTFields-drug
interaction after 72 hours of combined treatment was
1316 for paclitaxel, 23 for doxorubicin, 152 for cyclo-
phosphamide and 175 for DTIC (in U-118 glioma cells).
Thus a significantly reduced dose (1–3 orders of magni-
tude lower drug concentration) may be used in combina-
tion with TTFields to achieve the same level of efficacy.
Effect of combined paclitaxel and TTFields on VX2 tumors 
in rabbits
Prior to testing the combined efficacy of paclitaxel and
TTFields on VX2 tumors implanted within the kidneys of
rabbits, the dose-response of paclitaxel in this animal
tumor model was determined. A dose of Paclitaxel leading
consistently to a 15–20% inhibition in tumor growth (5
mg/rabbit) was chosen for subsequent combination
experiments with TTFields.
As seen in Figure 5, untreated tumors increased in volume
by a factor of 70 from baseline, Paclitaxel treated tumors
grew by a factor of 58 from baseline, TTFields treated
tumors grew by a factor of 34 from baseline and tumors
treated by TTFields-Paclitaxel combination grew by a fac-
tor of 22 from baseline. Thus the TTFields-Paclitaxel com-
bination treatment inhibited tumor growth by 69%
compared to the growth of control tumors, while Paclit-
axel alone inhibited tumor growth by 15% compared to
the growth of control tumors, and TTFields alone by 53%
compared to the growth of control tumors. Thus, additiv-
ity was seen between TTFields and Paclitaxel at the inten-
sity and concentration used. Differences between curves
were statistically significant (p < 0.01; ANOVA).
Pilot clinical trial in GBM patients
Twenty patients with histological diagnosis of GBM were
treated continuously for an average of 1 year (range 2.5–
24 months). Ten recurrent GBM patients were treated with
TTFields alone as salvage therapy. Ten newly diagnosed
Effect of light activated DTIC and TTFields (1.75 V/cm) on  cell proliferation of U-118 glioma cells, presented as percent  of viable cells compared to control Figure 4
Effect of light activated DTIC and TTFields (1.75 V/
cm) on cell proliferation of U-118 glioma cells, pre-
sented as percent of viable cells compared to control. 
Open Circles – 72 hours of DTIC treatment alone. Filled 
Circles – 72 h of Combined DTIC – TTFields treatment.
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Table 2: Calculated Combination Indexes for human breast 
cancer (MDA-MB-231) cells treated with paclitaxel, doxorubicin 
or cyclophosphamide in combination with TTFields.
Combination index
MDA-MB-231 cells
TTFields intensity
(V/cm)
Paclitaxel Doxorubicin Cyclophosphamide
CI40 CI50 CI50
0.625 - - 0.74
1.25 0.97 0.99 0.84
1.75 0.86 0.98 0.95BMC Medical Physics 2009, 9:1 http://www.biomedcentral.com/1756-6649/9/1
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GBM patients, that had undergone surgery and thereafter
received radiation therapy with adjuvant Temozolomide,
were treated with the combination of TTFields in parallel
to maintenance Temozolomide [14]. In both groups of
patients no device related serious adverse effects were
observed. The only device related toxicity reported was a
dermatitis which appeared most often (18 of 20 patients)
during the second month of treatment. The severity of the
dermatitis decreased upon use of topical corticosteroids
and periodic electrode relocation. The dermatitis contin-
ued for the duration of treatment and resolved completely
within days to weeks from treatment termination.
In the second group, no increase in Temozolomide related
adverse events was seen due to the combination with
TTFields (see Table 3).
As reported previously [1], both progression free survival
(PFS) and overall survival (OS) in the recurrent GBM sal-
vage therapy group were at least double that of concurrent
and historical controls, respectively. The efficacy of the
TTFields-Temozolomide combination in the second
group of patients was assessed using Kaplan Meier curves
[13] of PFS and OS. The Kaplan Meier curves for the PFS
of these patients, treated by combined TTFields – Temo-
zolomide are shown in Figure 6A. The median PFS of the
combination treated patients is 155 weeks versus 31
weeks for concurrent controls treated with maintenance
Temozolomide alone. Note that 5 of 10 patients are cur-
rently progression free. Figure 6B compares the OS of the
patients that received the combination treatment (Red
line) with a matched historical control (KPS>60, Median
age 54) (Black line [14]). It is seen that for the TTFields –
Temozolomide combination treated patients, the Median
OS > 39 months versus about 14.7 months for matched
historical control patients who received maintenance
Temozolomide alone. It should be noted that at the time
Effect of combined Paclitaxel/TTFields on VX2 tumors in Rabbits Figure 5
Effect of combined Paclitaxel/TTFields on VX2 tumors in Rabbits. A VX-2 Kidney tumor volumes were normalized 
to pre-treatment tumor volume (day 7) and are presented over time for; control (diamonds), 5 mg Paclitaxel (circles), TTFields 
(squares) and combined TTFields-Paclitaxel (triangles). The effect of combined TTFields and Paclitaxel is equal to the sum of 
the effects of either treatment alone at both time points measured during the study (2 and 3 weeks from treatment start; n = 
23; bars are standard errors of means). B Exemplary MRIs of the maximal contrast enhancing tumor area (demarcated by 
orange boarders) in the kidneys of rabbits in each of the experimental groups (sham control, Paclitaxel 5 mg, TTFields 2 V/cm, 
combined Paclitaxel and TTFields).
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Table 3: Toxicities by grade and causality in the newly diagnosed 
GBM patients treated with combined TTFields-Temozolomide.
Grade Causality assessment
I-II III-IV
Elevated LFTs 6/10 0/10 Anti Epileptic Drugs
Hyperglycemia 4/10 0/10 Oral Steroids
Anemia 6/10 0/10 Temozolomide
Thrombocytopenia 2/10 0/10 Temozolomide
Leucopenia 3/10 0/10 Temozolomide
Headache 2/10 0/10 Underlying disease
Seizures 1/10 0/10 Underlying disease
Dermatitis 10/10 0/10 NovoTTF-100ABMC Medical Physics 2009, 9:1 http://www.biomedcentral.com/1756-6649/9/1
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of this report 8 of 10 patients, receiving the TTFields-
Temozolomide combination treatment, are alive.
Discussion
Cancer treatment with drug combinations was introduced
in order to improve therapeutic indexes through dose
reduction of each drug and increase treatment efficacy. In
this study the exposure of cancer cells to combined chem-
otherapy and TTFields was studied in cell cultures, an ani-
mal tumor model and in a pilot clinical trial in recurrent
and newly diagnosed GBM patients. The results of this
study support the possibility that TTFields may be used,
not only as an effective stand alone anti-proliferation
agent (as shown previously in [1]), but also as an effective
adjuvant that enhances chemotherapy efficacy without an
increase in toxicity. In addition to this increase in efficacy,
these results raise the possibility of dose reduction of
chemotherapy when used in combination with TTFields.
This is of outmost importance since, at tolerable doses the
efficacy of available cancer therapeutic agents is often far
from optimum while being associated with a high degree
of toxicity.
With regards to the mechanisms involved, one may
assume that tumor cells are sensitized to TTFields by
chemotherapy, much like another well established physi-
cal therapy – ionizing radiation [8,18,19]. In the specific
case of Paclitaxel, one of the most commonly used treat-
ments for late-stage human breast cancer [20], the com-
bined effect may be attributed to their similar site of
action – the spindle microtubules [1,2,21]. Taxanes act by
stabilizing the link between individual tubulin dimmers
[21]. As illustrated schematically in Figure 7A taxanes
increase the length of tubulin filaments within the cell.
One of the mechanisms of action of TTFields is the mis-
alignment of mitotic spindle filaments as a result of
TTFields forces on tubulin chains [2]. The increase in fila-
ment length due to taxanes, increases the dipole moment
of these macromolecules, leading to an increase in the
TTFields induced forces and thus to a higher sensitivity of
the cell to TTFields (see Figure 7A).
Doxorubicin that has a broad spectrum of activity both in
experimental tumor models and in human malignancy,
affects both DNA and RNA synthesis [22]. Cyclophospha-
mide (an alkylating agent) inhibits DNA replication by
Kaplan Meier curves for A – progression free survival (PFS) and B – overall survival (OS) of newly diagnosed GBM patients  receiving either combined TTFields – Temozolomide treatment or Temozolomide treatment alone Figure 6
Kaplan Meier curves for A – progression free survival (PFS) and B – overall survival (OS) of newly diagnosed 
GBM patients receiving either combined TTFields – Temozolomide treatment or Temozolomide treatment 
alone. Red line – patients receiving combined TTFields – Temozolomide treatment (n = 10). Black line – concurrent/historical 
control patients that received Temozolomide treatment alone. A – The difference between the PFS curves is highly significant 
– Log-Rank Test (P = 0.0002), Hazard Ratio 3.32 (95%CI 1.9–5.9). B – The difference between the OS curves is highly signifi-
cant – (Log-Rank Test; P = 0.0018). Dashed lines mark the median values for each curve.
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interfering with the separation of the double stranded
DNA essential for transcription [23]. As illustrated in Fig-
ure 7B, since TTFields act at a completely different stage
(M phase) of the cell cycle from both these agents, addi-
tivity between chemotherapy and TTFields can be
expected.
Since the data for newly diagnosed GBM patients, which
points to well over a 300% increase in PFS and OS, was
obtained only with combination treatment, one cannot
directly separate the TTFields effects from the chemother-
apeutic effect. However, if we assume that the TTFields
therapeutic efficacy for newly diagnosed patients is simi-
lar to recurrent GBM, i.e. the median of OS is increased by
270% [1] while the published Temozolomide data indi-
cates an increase of about 20% in OS compared to ioniz-
ing radiation treatment alone [14], the results presented
in Figure 6 point towards additivity between TTFields and
Temozolomide. It is important to note that this significant
increase in efficacy was obtained without any increase in
device or drug related toxicity (see table 3).
An additional important finding is that both 24 h and 72
h combination treatments in-vitro result in severe irrevers-
ible cellular damage in contrast to chemotherapy alone.
This result strengthens the assumption that combination
therapy with TTFields may be much more effective than
treatment by individual agents.
Conclusion
The results of the present study support the notion that
TTFields may be used clinically not only as an anti-prolif-
eration agent as shown before [1], but also as effective sen-
sitizers of currently used chemotherapeutic agents. Such
sensitization was not shown to be associated with any
additional systemic toxicity. Moreover, as demonstrated
by the high DRIs calculated in this study, chemo/TTFields
combinations are expected to provide the same or even
greater therapeutic efficacy with much lower drug concen-
trations thus lowering further the overall toxicity.
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Appendix
Appendix A – Eligibility criteria for the pilot GBM trial
Inclusion criteria:
Histologically proven diagnosis of GBM.
Age over 18 years.
Karnofsky scale ≥ 70.
Participants of child bearing age had to be receiving effi-
cient contraception.
Willing and able to sign an informed consent prior to par-
ticipation in the study.
Exclusion criteria:
Patients actively participating in another clinical trial
Patients who received any anti-tumor therapy in the four
weeks prior to trial initiation (steroids are permitted; how-
ever, the dose must be stable or decreasing during the
trial).
Patients suspected of suffering from radiation necrosis
(according to a PET scan).
Pregnancy
Patients with one of the following co-morbidities:
Patients with an implanted pacemaker or documented
arrhythmias.
Significant renal, hepatic or hematologic disease.
Significant additional neurological disorder:
Seizure disorder unrelated to the patient's tumor
Pre-existing dementia
Progressive degenerative neurological disorder
Meningitis or encephalitis
Hydrocephalus associated with increased intracranial
pressure (ICP)
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